Satsuma Pharmaceuticals, Inc. (STSA) |
|
0.9821 0.012 (1.25%)
|
01-27 16:00 |
|
Open: |
0.9768 |
Pre. Close: |
0.97 |
|
High:
|
1.01 |
Low:
|
0.95 |
|
Volume:
|
84,310 |
Market Cap:
|
33(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:48:18 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 1.3 One year: 1.52 |
| Support: |
Support1: 0.92 Support2: 0.8 |
| Resistance: |
Resistance1: 1.12 Resistance2: 1.3 |
| Pivot: |
0.99  |
| Moving Average: |
MA(5): 0.99  MA(20): 0.96
MA(100): 3.28 MA(250): 3.87 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 48.8 %D(3): 56.3 |
| RSI: |
RSI(14): 43.7 |
| 52-week: |
High: 8.07 Low: 0.58 |
| Average Vol(K): |
3-Month: 853 (K) 10-Days: 174 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ STSA ] has closed above bottom band by 43.6%. Bollinger Bands are 91.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 36 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.01 - 1.02 |
1.02 - 1.02 |
|
Low:
|
0.94 - 0.94 |
0.94 - 0.95 |
|
Close:
|
0.97 - 0.98 |
0.98 - 0.99 |
|
Company Description |
|
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. |
Headline News |
Mon, 23 Jan 2023
Staidson's Respiratory Drug Shows Safety in Trial - Marketscreener.com
Sun, 22 Jan 2023
Cadrenal Therapeutics Stock (NASDAQ:CVKD), Quotes and News ... - Benzinga
Mon, 16 Jan 2023
Prepaid electricity crisis: 70 million meters may stop working next ... - News24
Mon, 12 Dec 2022
TXF Geneva 2022 On-Demand + TXF Sustainable Commodity ... - TXF
Mon, 14 Nov 2022
Why Is Satsuma Pharmaceuticals (STSA) Stock Down 80% Today? - InvestorPlace
Wed, 09 Nov 2022
STSA wins V.I. Championships for first time as five USVI age-group ... - Virgin Islands Daily News
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
33 (M) |
| Shares Float |
10 (M) |
|
% Held by Insiders
|
10.4 (%) |
|
% Held by Institutions
|
82.6 (%) |
|
Shares Short
|
348 (K) |
|
Shares Short P.Month
|
609 (K) |
Stock Financials |
|
EPS
|
-1.79 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.05 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-39.9 |
|
Return on Equity (ttm)
|
-67.9 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.89 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-53 (M) |
|
Levered Free Cash Flow
|
-33 (M) |
Stock Valuations |
|
PE Ratio
|
-0.56 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.47 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.62 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
